Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190181 | 1.00 | GAA (0.53) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL973145 | 1.00 | GAA (0.53) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL972237 | 0.79 | GAA (0.50) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL972236 | 0.79 | GAA (0.50) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL8188460 | 0.79 | GAA (0.50) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL5551834 | 0.79 | GAA (0.50) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL13186619 | 0.78 | GAA (0.51) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL218432 | 0.78 | GAA (0.64) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL218433 | 0.78 | GAA (0.64) | GAATP53MAPTKMT2ALMNA | |
| SCHEMBL25037566 | 0.77 | MAPT (0.43) | GAAMAPTKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1951678-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070260056-A1 | Process for Preparing Bicyclic Pyrazolyl | BRANDT THOMAS A | 2007-11-08 | — | — | US | disclosed |
| CN-101027285-A | Process for preparing bicyclic pyrazolyl compounds | PFIZER PROD INC (US) | 2007-08-29 | — | — | CN | disclosed |
| WO-2007046550-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7151097-B2 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1682554-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | Pfizer Products Incorporated (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044822-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | GAA 3711/4885TP53 4868/4885MAPT 3330/4885 |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | GAA 4860/4885TP53 4559/4885MAPT 4274/4885 |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | CNR2, CNR1, GPR18 | GAA 3711/4885TP53 4868/4885MAPT 3330/4885 |
| US-20070260056-A1 | Process for Preparing Bicyclic Pyrazolyl | CNR1, CNR2, GPR18 | GAA 2367/4885TP53 4860/4885MAPT 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.